» Articles » PMID: 14972776

Pharmacological Mechanisms of Naltrexone and Acamprosate in the Prevention of Relapse in Alcohol Dependence

Overview
Journal Am J Addict
Specialty Psychiatry
Date 2004 Feb 20
PMID 14972776
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Naltrexone and acamprosate may ultimately prove to be useful additions to pharmacotherapy for alcoholism by reducing relapse. Naltrexone is a relatively selective competitive antagonist at mu-opioid receptors, and this activity may explain its anti-relapse action either because endogenous opioids are involved in the positively reinforcing effects of alcohol and/or because these same transmitters are involved in the conditioned anticipation of these effects. In contrast, the pharmacology of acamprosate is still poorly understood. This is not surprising because it is a small flexible molecule with similarities to several neuro-active amino acids and is used in high doses. All these factors suggest that it may have multiple actions. Currently, the best explanation for the effects of acamprosate seems to be that it inhibits the glutamatergic transmitter system involved in both the negative reinforcing effects of alcohol and the conditioned "pseudo-withdrawal" that may be important in cue-induced relapse.

Citing Articles

Exploring the Role of DARPP-32 in Addiction: A Review of the Current Limitations of Addiction Treatment Pathways and the Role of DARPP-32 to Improve Them.

Greener M, Storr S NeuroSci. 2024; 3(3):494-509.

PMID: 39483434 PMC: 11523713. DOI: 10.3390/neurosci3030035.


A Review of the Characteristics of Clinical Trials and Potential Medications for Alcohol Dependence: Data Analysis from ClinicalTrials.gov.

Alshehri F Medicina (Kaunas). 2023; 59(6).

PMID: 37374305 PMC: 10300859. DOI: 10.3390/medicina59061101.


Substance use disorders: a comprehensive update of classification, epidemiology, neurobiology, clinical aspects, treatment and prevention.

Volkow N, Blanco C World Psychiatry. 2023; 22(2):203-229.

PMID: 37159360 PMC: 10168177. DOI: 10.1002/wps.21073.


The opioid antagonist naltrexone decreases seizure-like activity in genetic and chemically induced epilepsy models.

Sturgeon M, Langton R, Sharma S, Cornell R, Glykys J, Bassuk A Epilepsia Open. 2021; 6(3):528-538.

PMID: 34664432 PMC: 8408599. DOI: 10.1002/epi4.12512.


Pharmacotherapeutic management of co-morbid alcohol and opioid use.

Hood L, Leyrer-Jackson J, Olive M Expert Opin Pharmacother. 2020; 21(7):823-839.

PMID: 32103695 PMC: 7239727. DOI: 10.1080/14656566.2020.1732349.